Continuos Terlipressin Infusion in Septic Shock

• Status: Unknown status
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of terlipressin for treating septic shock.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University
• Collaborators: Anhui Provincial Hospital; Beijing 302 Hospital; China Medical University, China; Chinese PLA General Hospital; First Affiliated Hospital Bengbu Medical College; First People's Hospital of Foshan; Guangdong Province, Department of Science and Technology; Guangxi Medical University; Hainan People's Hospital; Health Science Center of Xi'an Jiaotong University; Health Science Center of Xi’an Jiaotong University; Jinling Hospital, China; Second Affiliated Hospital, Sun Yat-Sen University; Shanghai Changzheng Hospital; Sixth Affiliated Hospital, Sun Yat-sen University; West China Hospital; Wuhan Union Hospital, China; Xiangya Hospital of Central South University; ZhuHai Hospital
• Treatments: Lypressin; Norepinephrine; Terlipressin

Criteria

Inclusion Criteria:

• Septic shock was defined by the presence of two or more diagnostic criteria for the systemic inflammatory responsesyndrome, proven or suspected infection, and hypotension (exclusion of hypertention other than sepsis)

Exclusion Criteria:

• organ transplantation;

• pregancy or breast-feeding;

• malignancy or other irreversible disease or condition for which has a poor prognosis;

• acute coronary syndrome;

• chronic heart failure(NYHA III or IV)/cardiogenic shock;

• acute mesenteric ischemia;

• greater than 48 hours had elapsed since the patient met entry criteria;

• estimation of incomplite treament due to financial problem;

• use of terlipressin for blood pressure support before entry;

• Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;

• registration of other clinical trial which will affect the outcome of the current study